2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
16
Lymphoma, T-Cell
10
Recurrence
7
Lymphoma
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Large-Cell, Anaplastic
5
Immunoblastic Lymphadenopathy
4
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Follicular
3
Hodgkin Disease
3
Carcinoma, Non-Small-Cell Lung
3
Waldenstrom Macroglobulinemia
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Sezary Syndrome
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Burkitt Lymphoma
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Stomach Neoplasms
1
Smoking
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Rituximab
313
Cyclophosphamide
286
fludarabine phosphate
213
fludarabine
140
ibrutinib
121
Peripheral Blood Stem Cell Transplantation
116
venetoclax
108
Mycophenolic Acid
102
obinutuzumab
88
Lenalidomide
88
Bendamustine Hydrochloride
87
Whole-Body Irradiation
85
Filgrastim
84
Tacrolimus
78
Cyclosporine
78
Busulfan
70
Melphalan
65
Radiotherapy
63
Antilymphocyte Serum
61
Alemtuzumab
58
Etoposide
56
acalabrutinib
54
Methotrexate
49
ofatumumab
46
idelalisib
38
Cytarabine
33
Chlorambucil
33
zanubrutinib
31
sargramostim
30
Specimen Handling
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled